Evidence map›Paper›PMID 33353176›Full record

ArticleMolecules (Basel, Switzerland)2020

Macrocybin, a Natural Mushroom Triglyceride, Reduces Tumor Growth In Vitro and In Vivo through Caveolin-Mediated Interference with the Actin Cytoskeleton.

Marcos Vilariño, Josune García-Sanmartín, Laura Ochoa-Callejero, Alberto López-Rodríguez, Jaime Blanco-Urgoiti, Alfredo Martínez

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Antioxidant and Cytotoxic Effects and Identification ofFood technology and biotechnology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marcos VilariñoOncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0003-0060-5256
Josune García-SanmartínOncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0003-4391-5537
Laura Ochoa-CallejeroOncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0001-5366-6613
Alberto López-RodríguezCsFlowchem, Campus Universidad San Pablo CEU, Boadilla del Monte, 28668 Madrid, Spain.
Jaime Blanco-UrgoitiCsFlowchem, Campus Universidad San Pablo CEU, Boadilla del Monte, 28668 Madrid, Spain.
Alfredo MartínezOncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0003-4882-4044
Center for Biomedical Research of La Rioja · ESUniversidad San Pablo CEU · ES

Funding

Agencia de Desarrollo Económico de La Rioja (ADER) 2017-I-IDD-00067Fondos FEDER 2017-I-IDD-00067
6 · The paper itself

Abstract

Mushrooms have been used for millennia as cancer remedies. Our goal was to screen several mushroom species from the rainforests of Costa Rica, looking for new antitumor molecules. Mushroom extracts were screened using two human cell lines: A549 (lung adenocarcinoma) and NL20 (immortalized normal lung epithelium). Extracts able to kill tumor cells while preserving non-tumor cells were considered "anticancer". The mushroom with better properties was

Indexed as

AgaricalesAnimalsAntineoplastic AgentsBiological ProductsCell LineCell ProliferationDrug Screening Assays, AntitumorHumansMiceMice, Inbred NODMice, SCIDNeoplasms, ExperimentalAntineoplastic AgentsBiological Productsactin cytoskeletonCaveolin-1natural producttherapeutic triglyceridexenograft study

Identifiers

PMID33353176
PMCPMC7766322
OpenAlexW3112216602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.